title

Peter Sandercock and IST-3

International Journal of Stroke

0
Followers
0
Plays
Peter Sandercock and IST-3

Peter Sandercock and IST-3

International Journal of Stroke

0
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

Acute ischemic stroke is a major public health burden and globally a common cause of death and disability

Latest Episodes

Peter Sandercock and IST-3

Acute ischemic stroke is a major public health burden and globally a common cause of death and disability. Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.

12 MIN2010 AUG 17
Comments
Peter Sandercock and IST-3
the END

Latest Episodes

Peter Sandercock and IST-3

Acute ischemic stroke is a major public health burden and globally a common cause of death and disability. Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.

12 MIN2010 AUG 17
Comments
Peter Sandercock and IST-3
the END
hmly
himalayaプレミアムへようこそ聴き放題のオーディオブックをお楽しみください。